These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38841856)

  • 1. One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial.
    Hoshi RA; Alotaibi M; Liu Y; Watrous JD; Ridker PM; Glynn RJ; Serhan CN; Luttmann-Gibson H; Moorthy MV; Jain M; Demler OV; Mora S
    Arterioscler Thromb Vasc Biol; 2024 Jul; 44(7):e196-e206. PubMed ID: 38841856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
    Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
    Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol.
    Lawler PR; Akinkuolie AO; Chu AY; Shah SH; Kraus WE; Craig D; Padmanabhan L; Glynn RJ; Ridker PM; Chasman DI; Mora S
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28733430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
    Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.
    Kones R
    Drug Des Devel Ther; 2010 Dec; 4():383-413. PubMed ID: 21267417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Physical Activity With Bioactive Lipids and Cardiovascular Events.
    Hoshi RA; Liu Y; Luttmann-Gibson H; Tiwari S; Giulianini F; Andres AM; Watrous JD; Cook NR; Costenbader KH; Okereke OI; Ridker PM; Manson JE; Lee IM; Vinayagamoorthy M; Cheng S; Copeland T; Jain M; Chasman DI; Demler OV; Mora S
    Circ Res; 2022 Aug; 131(4):e84-e99. PubMed ID: 35862024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rosuvastatin in the management of dyslipidemia.
    Rubba P; Marotta G; Gentile M
    Vasc Health Risk Manag; 2009; 5(1):343-52. PubMed ID: 19436657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
    Mora S; Glynn RJ; Ridker PM
    Circulation; 2013 Sep; 128(11):1189-97. PubMed ID: 24002795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
    Kones R
    Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
    Ridker PM; MacFadyen JG; Wolfert RL; Koenig W
    Clin Chem; 2012 May; 58(5):877-86. PubMed ID: 22419750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
    Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
    Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group IIA Secretory Phospholipase A
    Akinkuolie AO; Lawler PR; Chu AY; Caulfield M; Mu J; Ding B; Nyberg F; Glynn RJ; Ridker PM; Hurt-Camejo E; Chasman DI; Mora S
    Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):1182-1190. PubMed ID: 31070471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
    O'Keefe JH; Carter MD; Lavie CJ; Bell DS
    Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
    Glynn RJ; Koenig W; Nordestgaard BG; Shepherd J; Ridker PM
    Ann Intern Med; 2010 Apr; 152(8):488-96, W174. PubMed ID: 20404379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.